Home › Compare › GKSDF vs ABBV
GKSDF yields 2.85% · ABBV yields 3.06%● Live data
📍 GKSDF pulled ahead of the other in Year 3
Combined, GKSDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GKSDF + ABBV for your $10,000?
Grupo KUO, S.A.B. de C.V., through its subsidiaries, manufactures and sells consumer business products, plastics, chemical products, and auto parts in Mexico, the United States, Spain, Belgium, and China. It operates through three segments: Consumer, Chemical, and Automotive. The Consumer segment primarily engages in the production and sale of pork meat; and consumer products, including processed food and beverages. The Chemical segment is involved in the manufacture and sale of plastics and chemical products, such as synthetic rubber and polymers. The Automotive segment engages in the manufacture and assembly of high-performance components and transmissions; and produces and markets automotive parts, such as pistons, brakes, bearings, gaskets, and seals primarily under the Tremec, Fritec, TF Victor, and Moresa brands. The company was formerly known as DESC, S.A.B. de C.V. and changed its name to Grupo KUO, S.A.B. de C.V. in March 2007. Grupo KUO, S.A.B. de C.V. was incorporated in 1973 and is headquartered in Mexico City, Mexico.
Full GKSDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.